Receive our The Drug Margin Playbook: Protecting High-Cost Infusion Revenue in Oncology eBook
For oncology practices, drug reimbursement is not just a line item – it is the financial foundation of the entire organization.
With drug acquisition costs rising, payer policies becoming more fragmented, and reimbursement methodologies growing more opaque, even small discrepancies in payment can erode margins at scale. Unlike denials, which are visible and actionable, underpayments – especially partial payments – often go undetected.
This creates a silent threat: revenue leakage that accumulates across drugs, payers, and patients.
This playbook outlines how oncology leaders can protect infusion drug margins through:
- Better visibility into reimbursement expectations
- Systematic detection of underpayments and partial payments
- Stronger payer accountability
- Centralized revenue intelligence
